Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Balzarotti

Showing results (21-30 of 72) with videos related to

Pageof 8
Sort By:
Cancers|December 11, 2022
Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell LymphomaAlessia Bari, Chiara Gerardi, Eleonora Allocati, et al.
Investigational New Drugs|February 1, 2021
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphomaMonica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, et al.
Cancers|June 26, 2026
Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective StudyDaniela Taurino, Giulia Figini, Francesca Ricci, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 17, 2009
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphomaLuca Castagna, Barbara Sarina, Elisabetta Todisco, et al.
Haematologica|January 25, 2012
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapyRaynier Devillier, Diane Coso, Luca Castagna, et al.
British Journal of Haematology|April 7, 2009
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapyLuca Castagna, Stefania Bramanti, Monica Balzarotti, et al.
Neurology|March 18, 2014
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 yearsAndrés J M Ferreri, Fabio Ciceri, Alba A Brandes, et al.
Leukemia Research|February 1, 2011
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experienceLuca Arcaini, Daniele Laszlo, Silvia Rizzi, et al.
The Oncologist|May 22, 2012
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphomaMichele Spina, Monica Balzarotti, Lilj Uziel, et al.
Frontiers in Oncology|November 22, 2021
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)Guido Gini, Alice Di Rocco, Luca Nassi, et al.
Pageof 8

Showing results (21-30 of 72) with videos related to

Sort By:
Pageof 8
Cancers|December 11, 2022
Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell LymphomaAlessia Bari, Chiara Gerardi, Eleonora Allocati, et al.
Investigational New Drugs|February 1, 2021
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphomaMonica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, et al.
Cancers|June 26, 2026
Stem Cell Mobilization and Autologous Transplantation Outcomes After First-Line R-DA-EPOCH in High-Risk DLBCL and HGBCL: A Single-Center Retrospective StudyDaniela Taurino, Giulia Figini, Francesca Ricci, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 17, 2009
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphomaLuca Castagna, Barbara Sarina, Elisabetta Todisco, et al.
Haematologica|January 25, 2012
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapyRaynier Devillier, Diane Coso, Luca Castagna, et al.
British Journal of Haematology|April 7, 2009
Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapyLuca Castagna, Stefania Bramanti, Monica Balzarotti, et al.
Neurology|March 18, 2014
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 yearsAndrés J M Ferreri, Fabio Ciceri, Alba A Brandes, et al.
Leukemia Research|February 1, 2011
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experienceLuca Arcaini, Daniele Laszlo, Silvia Rizzi, et al.
The Oncologist|May 22, 2012
Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphomaMichele Spina, Monica Balzarotti, Lilj Uziel, et al.
Frontiers in Oncology|November 22, 2021
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)Guido Gini, Alice Di Rocco, Luca Nassi, et al.
Pageof 8